Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Biospecifics Tech Cp (BSTC)

Biospecifics Tech Cp (BSTC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 419,725
  • Shares Outstanding, K 7,287
  • Annual Sales, $ 32,960 K
  • Annual Income, $ 20,050 K
  • 60-Month Beta 1.30
  • Price/Sales 12.92
  • Price/Cash Flow 18.91
  • Price/Book 4.17

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate 0.72
  • Number of Estimates 1
  • High Estimate 0.72
  • Low Estimate 0.72
  • Prior Year 0.59
  • Growth Rate Est. (year over year) +22.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
54.75 +5.21%
on 06/04/19
63.97 -9.96%
on 05/28/19
-4.73 (-7.59%)
since 05/24/19
3-Month
54.75 +5.21%
on 06/04/19
70.00 -17.71%
on 05/08/19
-7.41 (-11.40%)
since 03/22/19
52-Week
41.76 +37.93%
on 06/27/18
73.31 -21.43%
on 02/19/19
+13.69 (+31.18%)
since 06/22/18

Most Recent Stories

More News
ImmunoGen Plunges as FDA Recommends New Study for Lead Drug

FDA advises ImmunoGen (IMGN) to conduct a phase III study to evaluate the safety and efficacy of lead candidate - mirvetuximab soravtansine.

MRK : 85.51 (+1.11%)
IMGN : 1.87 (-4.59%)
RHHBY : 35.3850 (-0.60%)
BSTC : 57.60 (-1.42%)
Catalyst (CPRX) Q1 Loss Narrows, Firdapse Off to a Good Start

Catalyst (CPRX) posts narrower-than-expected loss and beats on revenues in the first quarter of 2019.

ESALY : 58.0150 (+0.44%)
CPRX : 3.61 (+0.84%)
REPH : 9.68 (-4.06%)
BSTC : 57.60 (-1.42%)
BioSpecifics Technologies Corp. Reports First Quarter 2019 Financial and Operating Results

BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed...

BSTC : 57.60 (-1.42%)
Zoetis (ZTS) Earnings Beat Estimates in Q1, Revenues Miss

Zoetis???s (ZTS) earnings beat estimates but sales miss the same in the first quarter of 2019.

ESALY : 58.0150 (+0.44%)
ZTS : 113.47 (+0.52%)
FGEN : 43.54 (-1.74%)
BSTC : 57.60 (-1.42%)
What's in Store for BioSpecifics (BSTC) This Earnings Season?

BioSpecifics Technologies (BSTC) will provide updates on Xiaflex and pipeline progress, when it releases first-quarter 2019 results.

ENDP : 3.59 (-6.51%)
NVO : 51.29 (+0.89%)
GSK : 40.59 (+0.79%)
BSTC : 57.60 (-1.42%)
Achaogen (AKAO) Files for Bankruptcy, Shares Plunge 65%

Achaogen (AKAO) files for bankruptcy in a district court. Shares slump 65% on the announcement.

ESALY : 58.0150 (+0.44%)
AKAO : 0.11 (unch)
ASRT : 3.05 (-3.48%)
BSTC : 57.60 (-1.42%)
Weekly Jobless Claims Lowest in Nearly 50 Years: 5 Top Picks

The U.S. labor market is the major driver of the bull run, which is more than a decade old.

DIN : 95.40 (+0.18%)
BIO : 301.00 (-1.17%)
PWR : 38.20 (-1.19%)
NSP : 122.79 (-0.46%)
BSTC : 57.60 (-1.42%)
Zogenix Gets Refusal to File Letter From FDA for Seizure Drug

Zogenix (ZGNX) receives a Refusal to File letter from the FDA regarding its NDA for Fintepla for the treatment of seizures associated with Dravet syndrome.

ESALY : 58.0150 (+0.44%)
GWPH : 172.27 (-0.78%)
ZGNX : 40.76 (+0.34%)
BSTC : 57.60 (-1.42%)
United Therapeutics Discontinues PAH Drug After Study Fails

United Therapeutics (UTHR) discontinues the development of esuberaprost, as the phase III study fails to meet primary endpoint.

ESALY : 58.0150 (+0.44%)
LLY : 115.63 (+0.12%)
UTHR : 76.06 (-1.87%)
BSTC : 57.60 (-1.42%)
3 Reasons Why BioSpecifics (BSTC) Is a Great Growth Stock

BioSpecifics (BSTC) is well positioned to outperform the market, as it exhibits above-average growth in financials.

BSTC : 57.60 (-1.42%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade BSTC with:

Business Summary

BIOSPECIFICS TECHNOLOGIES is engaged in the business of producing and licensing, for sale by other, a U.S. Food and Drug Administration (``FDA``) approved enzyme derived from collagenase, named Collagenase ABC, and researching, developing and clinically testing additional products derived therefrom for...

See More

Key Turning Points

2nd Resistance Point 60.15
1st Resistance Point 58.88
Last Price 57.60
1st Support Level 56.49
2nd Support Level 55.38

See More

52-Week High 73.31
Fibonacci 61.8% 61.26
Last Price 57.60
Fibonacci 50% 57.53
Fibonacci 38.2% 53.81
52-Week Low 41.76

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar